ramarketing-review:
How are drug regulators reshaping the path to approval?
In the pharma and biotech landscape, any regulatory change can have a direct impact on critical therapies reaching patients.
For development and manufacturing teams, bringing products to market with greater confidence relies on keeping up with evolving guidance from regulatory bodies, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
This month, we’re shining the spotlight on the rapidly shifting regulatory environment. So far in 2026, the FDA and EMA have taken various actions to drive meaningful change, with growing emphasis on earlier engagement, more structured data and stronger governance from initial development through to review.
As fresh guidance and evolving expectations reshape the path to approval, life science organisations that respond early will be better placed to keep pace, while those relying on legacy approaches may find the regulatory ground shifting beneath them.
The ramarketing review offers vital industry knowledge to keep you in the know, featuring a different ramarketing expert each month to deliver headline highlights.
If you’d like to receive updates straight to your inbox, sign up here.
Introducing March’s sector expert
Caitlin Richardson, Technical & Scientific Content Lead
Dr. Caitlin Richardson earned her Ph.D. in Cellular & Molecular Biology from Newcastle University, then blended hands‑on lab research with medical communications to craft literature reviews, seminar materials, and interactive infographics for global clients.
Her downstream‑processing work in medical device and biopharma firms refined her protein‑purification expertise and deepened her understanding of diagnostic kit and drug development.
Now Technical & Scientific Content Lead at ramarketing, Caitlin channels this experience into clear, strategically aligned content for biotech and pharmaceutical partners.
Rewriting the regulatory roadmap with more flexibility in evidence
The FDA is increasingly signaling a departure from one-size-fits-all drug development. Through a series of landmark draft guidances, the regulatory body is outlining a framework that favors evidence-based flexibility.
In January, the FDA issued draft guidance on approaches that combine existing knowledge with new trial data. This was closely followed by FDA leaders announcing a major shift in the agency’s longstanding evidentiary standards for drugs. The article specified that one adequate and well-controlled pivotal trial, supported by confirmatory evidence, should increasingly serve as the default option for approval in many cases.
In March, the FDA provided draft guidances aimed at streamlining unnecessary pharmacokinetic testing in biosimilar development and exploring alternatives to animal testing in drug development.
Although these changes offer life science organisations a chance to rethink their approach to clinical and non-clinical validation, some leaders in the field are uncertain. Some experts caution that a ‘one-trial default’ may increase the risk of false positives and introduce greater subjectivity into the regulatory review process.
Why Industry Is Questioning FDA’s Data-Sharing Push in Cell and Gene Therapy
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
CMC Guidance in 2026: FDA Officially Changed the Playbook
AI enters the rulebook and advanced therapies face a higher bar
Until recently, the use of artificial intelligence (AI) in drug development has moved faster than the regulatory frameworks around it, leaving many companies to shape governance, validation and documentation standards for themselves.
The joint EMA-FDA AI principles, published in January, signal a more coordinated approach. The agencies established 10 shared principles covering human-centric design, risk-based oversight and data governance. This framework requires companies to formally validate and document their AI-enabled workflows to support regulatory decision-making across global markets.
This raises the importance of formalising how AI-enabled workflows are developed, validated and documented if they are to support regulatory decision-making across markets.
Global regulators set out principles for safe AI across the medicines lifecycle
How AI is transforming the biopharmaceutical value chain from discovery to manufacturing
Earlier engagement and smarter submissions
A regulatory development that has drawn particular attention this year is the FDA’s Manufacturing PreCheck Pilot Program. Traditionally, companies develop and build a manufacturing site, prepare their CMC package and then face facility assessment as part of a specific product application. This can leave important manufacturing or inspection issues surfacing later in the process, when timelines are tighter and changes are harder to make. The FDA is now accepting applications for an initial cohort of new U.S. manufacturing facilities, with PreCheck designed to bring parts of that assessment forward and increase regulatory predictability before a filing is made.
For life science organisations, this raises the importance of bringing regulatory, CMC and manufacturing teams together earlier so site design, documentation and readiness are shaped with agency expectations in mind. By addressing these issues sooner, companies could reduce late-stage surprises and move forward with greater confidence.
More on this story…
FDA launches pilot programme to boost US manufacturing
3 biopharma CEOs explain why they are ‘authentically optimistic’ for 2026
Stay tuned for more ramarketing review instalments — who will be the guest expert next month? You’ll have to be subscribed to our mailing list to find out…
Related news, insight and opinion
Get regular updates in your inbox
Fields marked with a * are required